Fig. 3From: Economic evaluation of adding dapagliflozin to standard care in the treatment of chronic kidney disease: a systematic reviewIncremental QALY and LYG of dapagliflozin plus standard therapy versus Standard therapy on the lifetime horizonBack to article page